Keum-Ju Choi

Keum-Ju Choi

Auto-generated profile, based on publicly available information

Keum-Ju Choi

Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu Catholic University School of Medicine, Daegu, South Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Tuberculosis and Respiratory Diseases
Verified
Journal Article
Open access
PDF file
KCKeum-Ju Choi
Keum-Ju Choi
HHHyo-Lim Hong
Hyo-Lim Hong
Eun Jin KimEun Jin Kim
Eun Jin Kim
Coronavirus disease 2019 (COVID-19) can manifest from asymptomatic to acute respiratory distress syndrome (ARDS). COVID-19 associated pneumonia develops into ARDS due to rapid progression of hypoxia. Although arterial blood gas analysis (ABGA) should be implemented to confirm this deterioration, it is not easy to obtain such tests in the COVID-19 environment. Therefore, this study was conducted to determine whether oxygen saturation (SpO2) and SpO2/fraction of inhaled oxygen (FiO2) (SF ratio) predicts ARDS and mortality. This was a retrospective cohort study that enrolled COVID-19 pneumonia patients requiring oxygen therapy from Feb 2020 to May 2020. Of 100 COVID-19 pneumonia cases, we compared 59 cases of pneumonia requiring oxygen, divided into ARDS and non-ARDS pneumonia requiring oxygen. The factors affecting mortality were investigated. At the time of admission, the SpO2, FiO2, and SF ratios of the ARDS group were significantly different from those of the non-ARDS pneumonia requiring oxygen support group (P <0.001, respectively). With respect to predicting occurrence of ARDS, the SF ratio on admission and the SF ratio at exacerbation showed an overall area under the curve of 85.7% and 88.8% (P < 0.001, respectively). Multivariate Cox regression analysis identified the SF ratio at exacerbation (HR, 0.916; 95% CI, 0.846-0.991; P = 0.029) and National Early Warning Score (NEWS) (HR, 1.277; 95% CI, 1.010-1.615; P = 0.041) as significant predictors of mortality. The SF ratio on admission and the SF ratio at exacerbation can predict occurrence of ARDS. The SF ratio at exacerbation and NEWS has a significant effect on mortality.

28 February 2023 in Acute and Critical Care
Verified
Journal Article
Open access
KCKeum-Ju Choi
Keum-Ju Choi
SJSoo Kyun Jung
Soo Kyun Jung
KKKyung Chan Kim
Kyung Chan Kim
Eun Jin KimEun Jin Kim
Eun Jin Kim
Background: The guidelines recommend the use of dexamethasone 6 mg or an equivalent dose in patients with coronavirus disease 2019 (COVID-19) who require supplemental oxygen. Given that the severity of COVID-19 varies, we investigated the effect of a pulse dose of corticosteroids on the clinical course of critically ill patients with COVID-19.Methods: This single-center, retrospective cohort study was conducted between September and December 2021, which was when the Delta variant of the COVID-19 virus was predominant. We evaluated the mortality and oxygenation of severe to critical COVID-19 cases between groups that received dexamethasone 6 mg for 10 days (control group) and methylprednisolone 250 mg/day for 3 days (pulse group).Results: Among 44 patients, 14 and 30 patients were treated with control steroids and pulse steroids, respectively. There was no difference in disease severity, time from COVID-19 diagnosis to steroid administration, or use of remdesivir or antibacterial agents between the two groups. The pulse steroid group showed a significant improvement in oxygenation before and after steroid treatment (P<0.001) compared with the control steroid group (P=0.196). There was no difference in in-hospital mortality (P=0.186); however, the pulse steroid group had a lower mortality rate (23.3%) than the control steroid group (42.9%). There was a significant difference in the length of hospital stay between both two groups (P=0.039). Conclusions: Pulse steroids showed no mortality benefit but were associated with oxygenation improvement and shorter hospital stay than control steroids. Hyperglycemia should be carefully monitored with pulse steroids.

18 May 2025 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
SJSoo Kyun Jung
Soo Kyun Jung
KCKeum-Ju Choi
Keum-Ju Choi
A 36-year-old female patient who did not have a previous history of any disease visited our institution because of shortness of breath. The patient was first diagnosed with diabetes upon admission. Chest computed tomography (CT) scan showed a lesion that completely obstructed the left main bronchus and pneumonia. Due to hypoxia, the patient was placed on mechanical ventilation and admitted to the intensive care unit. Bronchoscopy was performed, and results revealed complete atelectasis with a soft tissue mass at the left main bronchus. Bronchoscopic biopsy confirmed that the patient's condition was endobronchial mucormycosis. Treatment with liposomal amphotericin B was started. After 1 week, atelectasis improved based on the chest radiography result. The patient was successfully extubated. However, 4 weeks after treatment, bronchoscopy still showed complete atelectasis with purulent secretion and a soft tissue mass. After 6 weeks, liposomal amphotericin B was switched to isavuconazole, with a duration of 2 months. After completing the treatment, bronchoscopy showed no endobronchial lesion. Herein, we present a rare case of rapidly progressing endobronchial mucormycosis in a young patient who did not have a previous history of any disease and who was successfully managed with pharmacological therapy.

14 September 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
SJSoo Kyun Jung
Soo Kyun Jung
KCKeum Ju Choi
Keum Ju Choi
Eun Jin KimEun Jin Kim
Eun Jin Kim
Background/Objectives: Severe community-acquired pneumonia (CAP) can be fatal and requires the rapid and appropriate administration of antibiotics. Rapid multiplex PCR pneumonia panels are widely used tools for antimicrobial de-escalation and stewardship; however, their role in driving antibiotic escalation in severe pneumonia requiring intensive care is less well characterized. Methods: We retrospectively analyzed 288 adults with severe CAP who were admitted to the intensive care unit (ICU) of a tertiary hospital and underwent lower-respiratory BioFire FilmArray Pneumonia Panel (BFPP) testing between April 2023 and September 2024. The primary outcome was antibiotic escalation, defined as addition of an agent or a change to broader-spectrum therapy after the BFPP result, and its associated factors. Secondary outcomes were in-hospital mortality, hospital and ICU length of stay (LOS), and ventilator duration according to the antibiotic escalation. Results: Patients were elderly (median 72 years old; 60.8% male) and critically ill (median SOFA 8; median APACHE-II 19; shock 49.0%; mechanical ventilation 56.9%). The panel was positive in 66.3% of cases, and results were obtained with a median turnaround time of 2 h versus 67 h for sputum culture. After the panel, antibiotics were escalated in 34.0% of cases, de-escalated in 2.8%, discontinued in 0.7%, and unchanged in 62.5%. Escalation was independently associated with resistance gene detection (adjusted odds ratio [aOR] 3.15, 95% CI 1.71–5.82), panel positivity (aOR 1.97, 95% CI 1.02–3.80), and SOFA score (aOR 1.10 per point, 95% CI 1.01–1.19). Thirty-day mortality, in-hospital mortality, hospital LOS, ICU LOS, and ventilator duration did not differ between escalation and non-escalation groups. Conclusions: In severe CAP requiring intensive care and managed with a comparatively narrow initial empirical regimen, panel testing was predominantly followed by antibiotic escalation rather than de-escalation, particularly when resistance genes were detected. No statistically measurable difference in clinical outcomes was observed, but the study was not powered to exclude any clinically meaningful benefit or harm of escalation.